Expert-led tax essentials delivering practical insights and strategic foresight. Learn more.
The year was the strongest on record for the biotechnology sector but its leaders remain concerned over the fate of the R&D Tax Incentive.
The latest tagline to hit consumers is ‘Have sex. Save a life. Save the world.’ And Grant Thornton's client, Hero Condoms, promotes it proudly.
Disruption is a wonderful thing - unless you're on the wrong side of it. Controversial commentator Andrew Keen considers the adverse impact that radical technologies will have on mid-sized companies.
The 2016 Biotechnology Industry Position Survey reveals that Australian life sciences companies have attracted well over $2 billion in deal flow over the last 18 months.
Recent budget announcements will see residential care providers struggle to remain viable. While there was some good news with the announcement of 1,286 new places and increased viability supplements for rural and remote providers, this will mean little to the large number of providers already operating on slender margins.
After much anticipation, APRA has finally released a discussion paper, proposed prudential standards and reporting framework for their new role as the Private Health Insurance industry supervisor which is expected to take affect from 1 July 2015.